HOME > ACADEMIA
ACADEMIA
- Gynecologist Stresses Urgent Need to Resume HPV Vaccinations, Cites Age Disparity in Cervical Cancer Risk
July 10, 2019
- Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
- Univ. of Tokyo, 3H to Start Matching Program for Rare Disease R&D
May 21, 2019
- Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
May 17, 2019
- Treatment with Corticosteroids Strongly Recommended for Sclerosing Cholangitis: New Guidelines
May 9, 2019
- Risk of Relapse Will Be Challenge for CAR-T Cell Therapy: Immunologist
May 8, 2019
- Niigata Univ., Eisai Team Up to Develop Pancreatic Cancer Drug Using Highly Absorbed Peptide
May 7, 2019
- Revised Hypertension Treatment Guidelines Set Stricter Blood Pressure Reduction Target
April 23, 2019
- Xofluza Shouldn’t Be Used Alone for Hong Kong Flu: Specialist
April 8, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
- Discuss Biosimilar Pricing Separate from High-Cost Medical Expense Benefits: Prof.
March 20, 2019
- NCNP to Set Up New Council to Accelerate Clinical Development of Neuromuscular Disorder Treatments
March 18, 2019
- Feburic Prevents Cerebral, Cardiorenovascular Events: Japan Multicenter Study
March 13, 2019
- Investigators Calling Off Trials on First Hyperlactacidemia Drug with No Significant Improvement Shown
February 28, 2019
- Keio Researchers Start Studying ReQuip for ALS after iPS Screening
February 25, 2019
- Revised Hyperuricemia Treatment Guidelines Recommend Uric Acid Production Inhibitors to Prevent Kidney Function Decline
January 21, 2019
- Concomitant Insulin a Must for Suglat Use in Type 1 Diabetes: Specialist
January 18, 2019
- 8-Week Treatment with Maviret a Promising First-Line Option for Hepatitis C: Hepatologist
January 11, 2019
- Tokyo Medical and Dental Univ. to Launch Investigator-Led Trial for JAK Inhibitor for CAEBV
January 10, 2019
- Health Economist Calls for Robust Appraisal Process in Japan CEA System
November 20, 2018
ページ
Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…